High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

Horton, 2007, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem. Sci., 32, 71, 10.1016/j.tibs.2006.12.008

Cao, 2008, Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease, Endocr. Metab. Immune Disord. Drug Targets., 8, 238, 10.2174/187153008786848286

Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J. Lipid Res., 50, S172, 10.1194/jlr.R800091-JLR200

Seidah, 2009, PCSK9 as a therapeutic target of dyslipidemia, Expert Opin. Ther. Targets., 13, 19, 10.1517/14728220802600715

Lambert, 2006, PCSK9: a promising therapeutic target for dyslipidemias, Trends Endocrinol. Metab., 17, 79, 10.1016/j.tem.2006.02.001

Mousavi, 2009, The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis, J. Intern. Med., 266, 507, 10.1111/j.1365-2796.2009.02167.x

Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J. Clin. Endocrinol. Metab., 94, 2537, 10.1210/jc.2009-0141

McNutt, 2009, Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells, J. Biol. Chem., 284, 10561, 10.1074/jbc.M808802200

Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200

Qian, 2007, Secreted proprotein convertase subtilisin/kexin-type 9 reduces low-density lipoprotein receptor through receptor-mediated endocytosis, J. Lipid Res., 48, 1488, 10.1194/jlr.M700071-JLR200

Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA., 105, 1820, 10.1073/pnas.0712064105

Graham, 2007, Antisense inhibition of proprotein convertase subtilisin kexin 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res., 48, 763, 10.1194/jlr.C600025-JLR200

Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest., 116, 2995, 10.1172/JCI29383

Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post- endoplasmic reticulum compartment, Proc. Natl. Acad. Sci. USA., 102, 2069, 10.1073/pnas.0409736102

Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J. Biol. Chem., 279, 50630, 10.1074/jbc.M410077200

Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200

Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. USA., 101, 7100, 10.1073/pnas.0402133101

Schmidt, 2008, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo, Biochem. Biophys. Res. Commun., 370, 634, 10.1016/j.bbrc.2008.04.004

Li, 2007, Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity, Biochem. J., 406, 203, 10.1042/BJ20070664

McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem., 282, 20799, 10.1074/jbc.C700095200

Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200

Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc. Natl. Acad. Sci. USA., 106, 9820, 10.1073/pnas.0903849106

Duff, 2009, Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor, Biochem. J., 419, 577, 10.1042/BJ20082407

Ni, 2010, A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen binding fragment inhibits PCSK9 internalization and restores LDL-uptake, J. Biol. Chem., 285, 12882, 10.1074/jbc.M110.113035

Maxwell, 2005, Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia, Curr. Opin. Lipidol., 16, 167, 10.1097/01.mol.0000162321.31925.a3

Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161

Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum. Mutat., 26, 497, 10.1002/humu.9383

Humphries, 2009, Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9, Clin. Chem., 55, 2153, 10.1373/clinchem.2009.129759

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N. Engl. J. Med., 354, 1264, 10.1056/NEJMoa054013

Fasano, 2007, A novel loss-of-function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler. Thromb. Vasc. Biol., 27, 677, 10.1161/01.ATV.0000255311.26383.2f

Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet., 79, 514, 10.1086/507488

Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol., 29, 2191, 10.1161/ATVBAHA.109.194191

Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA., 102, 5374, 10.1073/pnas.0501652102

Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler. Thromb. Vasc. Biol., 26, 1094, 10.1161/01.ATV.0000204337.81286.1c

Dong, 2010, Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters, J. Lipid Res., 51, 1486, 10.1194/jlr.M003566

Alborn, 2007, Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol, Clin. Chem., 53, 1814, 10.1373/clinchem.2007.091280

Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J. Lipid Res., 49, 394, 10.1194/jlr.M700437-JLR200

Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J. Lipid Res., 51, 140, 10.1194/jlr.M900273-JLR200

Zineh, 2006, Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study, Pharmacotherapy., 26, 1572, 10.1592/phco.26.11.1572

Welder, 2006, Complementary and alternative medicine use among individuals participating in research: implications for research and practice, Pharmacotherapy., 26, 1794, 10.1592/phco.26.12.1794

Troutt, 2010, Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels, J. Lipid Res., 51, 345, 10.1194/jlr.M000620

Mayne, 2008, Plasma PCSK9 levels are significantly modified by statins and fibrates in humans, Lipids Health Dis., 7, 22, 10.1186/1476-511X-7-22

Cariou, 2010, Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients, Atherosclerosis, 10.1016/j.atherosclerosis.2010.04.015